美股異動|小鵬汽車盤前升超4% 績後獲星展上調目標價至17美元並上調銷量預測
小鵬汽車(XPEV.US)盤前升超4.2%,報11.87美元。消息面上,星展近日發表報吿指,小鵬P7+和MONA M03型號的銷售積壓強勁,加上小鵬將於明年推出的四款新型號,將2025和2026財年銷量增長預測分別上調至65%和25%,即約30.8萬和38.5萬台。鯤鵬超級電動系統(可在純電動和增程駕駛之間無縫切換)在EREV市場的擴張將加速未來的增長。星展指,因銷售及利潤前景改善,將小鵬汽車ADR目標價由15美元上調至17美元,維持“買入”評級。(格隆匯)

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.